s early as the 1920s, the insurance industry had identified several factors that predict future cardiovascular disease (CVD) events. In the 1940s, the Framingham Heart Study formalized and served as a leader in the CVD risk prediction process. In recent years, various CVD risk prediction models have been developed and recommended in clinical practice guidelines. Much of the focus has been on high-income countries, where CVD risk prediction instruments have included several traditional risk factors, such as age, sex, race, blood pressure, hypertension treatment, lipid levels, smoking status, presence or absence of diabetes (1), and sometimes statin and aspirin treatment status. In the United States, drug therapies to lower lipid levels and blood pressure are recommended for adults aged 40 to 79 years without CVD who have a 10-year risk for atherosclerotic CVD (ASCVD) of 7.5% or greater (statins) or 10% or greater (antihypertensive medications) based on pooled cohort risk equations from the American College of Cardiology and American Heart Association (ACC/AHA) (2, 3). The U.S. Preventive Services Task Force somewhat guardedly recommends aspirin therapy for primary prevention, primarily for adults aged 50 to 59 years with a 10-year ASCVD risk of 10% or greater (4) .
The World Health Organization (WHO) and others have endorsed and facilitated screening for high CVD risk in middle-and low-income countries by providing risk prediction charts that require limited or no laboratory testing (5) . In their current report, Lu and colleagues provide estimates for the prevalence of high CVD risk (defined as a 10-year predicted CVD risk ≥10%), derived using WHO CVD risk prediction charts, in a cohort of approximately 1.7 million Chinese adults aged 35 to 75 years with no history of a CVD event (6) . The authors report an overall prevalence of 9.5%, with substantial heterogeneity by age, location (higher among those living in rural areas), body mass index, and socioeconomic status. Hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or antihypertensive drug treatment) was almost universally identified in persons at high risk for CVD, and there was substantial clustering of hypertension with diabetes as well as with smoking (in men). In the high-risk group, treatment with statins and aspirin was infrequent (0.6% and 2.4%, respectively). The prevalence of reported antihypertensive drug therapy was higher but still markedly insufficient at 31.8%.
Earlier reports from China identified deficiencies in detecting and treating traditional CVD risk factors, such as high blood pressure (7). However, Lu and colleagues suggest that treatment with statins, aspirin, and antihypertensive drugs is uncommon even in high-risk adults, who are most likely to benefit from such therapies. The prevalence rates they estimated probably represent a substantial underestimation of the true burden of illness due to CVD in China. In a supplement to their article, the authors report that the risk prediction charts they used were designed for Region B of the Western Pacific, which includes 22 countries, and thus were not country specific. These charts predict the risk for fatal or nonfatal stroke and myocardial infarction but do not include coronary heart disease (CHD) events due to other causes. The charts were developed from data collected almost 2 decades ago as part of the Comparative Risk Assessment project. Since then, China has experienced a rapid epidemiologic transition that makes use of more current and locally validated risk prediction instruments preferable. The recently published China-PAR (Prediction for ASCVD Risk in China) instrument, which includes both nonfatal myocardial infarction or CHD death and fatal or nonfatal stroke as ASCVD events (8), might provide a more accurate estimate of CVD risk in China. Although the authors compared their estimates of high CVD risk prevalence with those based on another risk score specific to China, the latter also is based on relatively old data (collected between 1983 and 2000) (9) . We found further evidence that the WHO risk prediction charts underestimate the true burden of illness due to CVD when we compared estimates of high CVD risk (10-year predicted ASCVD risk, ≥10%) based on the ACC/AHA pooled cohort risk equations (which include CHD deaths, nonfatal myocardial infarction, and fatal or nonfatal stroke as CVD end points) with those based on the WHO risk prediction charts recommended for Region A of the Americas (Canada, Cuba, and the United States). Using data from 5246 U.S. adults aged 40 to 79 years without a history of CHD or stroke who participated in NHANES (National Health and Nutrition Examination Survey) 2011 to 2012 and 2013 to 2014 (10) was similar, when high ASCVD risk was defined on the basis of the ACC/AHA pooled cohort risk equations. Regardless of the method used to define high CVD risk, the percentages of medication use among U.S. adults were substantially higher than those in the study by Lu and colleagues.
The fact that the estimates reported by Lu and colleagues very likely underrepresent the true burden of illness due to CVD in China underscores the importance of the authors' conclusion that CVD risk identification and targeted therapy are urgently needed in China. Regardless of that country's true CVD risk, it is too high and the trajectory is headed toward progressive worsening unless steps are taken to drastically improve awareness, treatment, and control of CVD risk factors. The report by Lu and colleagues is an important call to action. It also should serve as a wake-up call for many other highly populated middle-and lowincome countries where the CVD risk factor profile is worsening faster than the current health sector can respond to it. We hope that it will motivate these nations to take more decisive action.
